Gilead Gilead Sciences has provided its antiviral therapy, remdesivir, to the Ministry of Health of Ethiopia to help combat the country’s first outbreak of Marburg Virus Disease (MVD). The contribution underscores Gilead’s commitment to global health and rapid action during public health crises.
“At Gilead, we believe access to life-saving medicines should not be limited by geography or circumstance,” said Anu Osinusi, Vice President of Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead Sciences. “Our donation of remdesivir reflects our responsibility to act quickly and decisively when global health emergencies arise.”
Marburg Virus Disease is a rare but severe hemorrhagic fever with high mortality rates, requiring swift intervention to prevent further spread. Gilead is working closely with the Ministry of Health of Ethiopia to provide remdesivir for emergency use. This collaboration aims to strengthen outbreak response and treat affected communities.